Bristol-Myers Squibb has signed another deal to build its capabilities in antibody-drug conjugates for cancer, paying $100 million upfront to take control of an Orum Therapeutics candidate with a ...

Operational risk is often described as the “silent disruptor” of the financial world. Unlike credit risk or market risk, which are measurable and frequently modeled with precision, operational risk is ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Rebecca McClay has 10+ years of experience writing and editing content. Rebecca is an expert in personal finance, business, and financial markets. She received her master's in business journalism from ...